The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Eli Lilly (LLY) earns a BUY rating with a $1,220 price target, backed by 47% revenue growth and four straight EPS beats.
Novo Nordisk (NVO) trades at a forward P/E of 14 with just 2% revenue growth, making Lilly's premium valuation at 24x look justified.
Retatrutide's BLA submission planned for Q1 2027 is the bull catalyst that could drive shares to $1,382, while pricing declines are the primary risk.
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.